FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601612985> ?p ?o ?g. }

• W2601612985 abstract "Intravenous iron is widely used to control anemia in dialysis patients and limits costs related to erythropoiesis-stimulating agents (ESA). Current guidelines do not clearly set upper limits for serum ferritin (SF) and transferrin saturation (TSAT). International surveys such as the Dialysis Outcomes and Practice Patterns Study (DOPPS) showed that this lack of upper limits potentially led nephrologists to prescribe iron infusions even for patients with a high SF. Recent publications have suggested a risk of short- and long-term adverse effects related to iron overload. We conducted a proof of concept study to assess the impact of reducing intravenous iron administration. In a prospective 8-month study conducted in a hospital dialysis unit, we assessed the impact of a strategy designed to reduce iron infusions. Instead of the usual strategy targeting 30–50% TSAT irrespective of SF, intravenous iron was administered if and only if TSAT was below 20% and SF below 200 μg/L. Routine practices for ESA remained unchanged: hemoglobin target 10–12 g/dL; ESA delivered monthly and dose corrected by 25% as necessary; ESA discontinued temporarily if hemoglobin >13 g/dL; methoxy polyethylene glycol-epoetin beta generally used. Tests were ordered monthly to monitor hemoglobin. Intravenous iron was administered weekly and ESA monthly. Baseline and 6-month TSAT, SF and hemoglobin levels were compared. Six-month data were available for 45 patients (31 M/14 F; 67.6 ± 14.0 y; 53.9 ± 85.7 months on dialysis). Patients experienced the following comorbidities: ischemic heart disease (n = 29, 44%), diabetes mellitus (n = 14; 31%), malignant disease (n = 11; 24%), transplantation (n = 11; 24%) and severe heart failure (n = 6; 13%). The mean weekly dose of iron declined from 77.8 ± 87.6 to 24.4 ± 52.9 mg per patient (p = 0.0003). SF decreased from 947.7 ± 1056.4 to 570.7 ± 424.4 μg/L (p = 0.0001), and TSAT from 41.5 ± 22.4 to 32.6 ± 13.7% (p = 0.01). Hemoglobin levels remained stable (11.13 ± 1.05 vs. 11.00 ± 1.16 g/dL, p = 0.54) as did ESA dose (126.4 ± 91.9 vs. 108.2 ± 112.7 μg/28 days, p = 0.07). Our study suggests that a regular hemoglobin level can be maintained using regular ESA doses combined with intravenous iron doses adapted to TSAT and SF thresholds lower than those used in routine practice. This strategy reduces the risk of iron overload." @default.
• W2601612985 created "2017-04-07" @default.
• W2601612985 creator A5010871542 @default.
• W2601612985 creator A5014982727 @default.
• W2601612985 creator A5056550280 @default.
• W2601612985 creator A5065136658 @default.
• W2601612985 creator A5084509236 @default.
• W2601612985 date "2017-03-20" @default.
• W2601612985 modified "2023-10-10" @default.
• W2601612985 title "Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study" @default.
• W2601612985 cites W1571358690 @default.
• W2601612985 cites W1909632531 @default.
• W2601612985 cites W1964685535 @default.
• W2601612985 cites W1965781512 @default.
• W2601612985 cites W1966403386 @default.
• W2601612985 cites W2004652263 @default.
• W2601612985 cites W2007852467 @default.
• W2601612985 cites W2025111767 @default.
• W2601612985 cites W2026661079 @default.
• W2601612985 cites W2033803279 @default.
• W2601612985 cites W2038126313 @default.
• W2601612985 cites W2040029744 @default.
• W2601612985 cites W2041248480 @default.
• W2601612985 cites W2051818677 @default.
• W2601612985 cites W2052815827 @default.
• W2601612985 cites W2056969309 @default.
• W2601612985 cites W2072506649 @default.
• W2601612985 cites W2079565355 @default.
• W2601612985 cites W2084203475 @default.
• W2601612985 cites W2085784457 @default.
• W2601612985 cites W2094883077 @default.
• W2601612985 cites W2099927570 @default.
• W2601612985 cites W2104810766 @default.
• W2601612985 cites W2107215009 @default.
• W2601612985 cites W2108858457 @default.
• W2601612985 cites W2109126331 @default.
• W2601612985 cites W2115208217 @default.
• W2601612985 cites W2116948290 @default.
• W2601612985 cites W2120501201 @default.
• W2601612985 cites W2128490296 @default.
• W2601612985 cites W2128540381 @default.
• W2601612985 cites W2135454486 @default.
• W2601612985 cites W2141067396 @default.
• W2601612985 cites W2144758554 @default.
• W2601612985 cites W2147671904 @default.
• W2601612985 cites W2148669301 @default.
• W2601612985 cites W2148904142 @default.
• W2601612985 cites W2149965056 @default.
• W2601612985 cites W2158623958 @default.
• W2601612985 cites W2190362855 @default.
• W2601612985 cites W2209943919 @default.
• W2601612985 cites W2325969870 @default.
• W2601612985 cites W2396894795 @default.
• W2601612985 cites W2580449060 @default.
• W2601612985 cites W2584947097 @default.
• W2601612985 cites W2596955988 @default.
• W2601612985 cites W4239234884 @default.
• W2601612985 cites W3149132779 @default.
• W2601612985 doi "https://doi.org/10.1186/s12882-017-0513-x" @default.
• W2601612985 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5358046" @default.
• W2601612985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28320343" @default.
• W2601612985 hasPublicationYear "2017" @default.
• W2601612985 type Work @default.
• W2601612985 sameAs 2601612985 @default.
• W2601612985 citedByCount "8" @default.
• W2601612985 countsByYear W26016129852018 @default.
• W2601612985 countsByYear W26016129852020 @default.
• W2601612985 countsByYear W26016129852021 @default.
• W2601612985 countsByYear W26016129852022 @default.
• W2601612985 crossrefType "journal-article" @default.
• W2601612985 hasAuthorship W2601612985A5010871542 @default.
• W2601612985 hasAuthorship W2601612985A5014982727 @default.
• W2601612985 hasAuthorship W2601612985A5056550280 @default.
• W2601612985 hasAuthorship W2601612985A5065136658 @default.
• W2601612985 hasAuthorship W2601612985A5084509236 @default.
• W2601612985 hasBestOaLocation W26016129851 @default.
• W2601612985 hasConcept C126322002 @default.
• W2601612985 hasConcept C141071460 @default.
• W2601612985 hasConcept C153852466 @default.
• W2601612985 hasConcept C197934379 @default.
• W2601612985 hasConcept C2777417653 @default.
• W2601612985 hasConcept C2778063415 @default.
• W2601612985 hasConcept C2778248108 @default.
• W2601612985 hasConcept C2778319317 @default.
• W2601612985 hasConcept C2778917026 @default.
• W2601612985 hasConcept C2779978075 @default.
• W2601612985 hasConcept C3020614022 @default.
• W2601612985 hasConcept C54847362 @default.
• W2601612985 hasConcept C71924100 @default.
• W2601612985 hasConceptScore W2601612985C126322002 @default.
• W2601612985 hasConceptScore W2601612985C141071460 @default.
• W2601612985 hasConceptScore W2601612985C153852466 @default.
• W2601612985 hasConceptScore W2601612985C197934379 @default.
• W2601612985 hasConceptScore W2601612985C2777417653 @default.
• W2601612985 hasConceptScore W2601612985C2778063415 @default.
• W2601612985 hasConceptScore W2601612985C2778248108 @default.
• W2601612985 hasConceptScore W2601612985C2778319317 @default.
• W2601612985 hasConceptScore W2601612985C2778917026 @default.
• W2601612985 hasConceptScore W2601612985C2779978075 @default.
• W2601612985 hasConceptScore W2601612985C3020614022 @default.

• next